AI Article Synopsis
- Green et al. introduced a new pretargeted radioimmunotherapy (RIT) method for treating non-Hodgkin lymphoma (NHL) and multiple myeloma.
- This innovative therapy utilizes a bispecific monoclonal antibody targeting CD38, which is highly expressed in these cancers.
- Preclinical results have shown impressive outcomes, highlighting the potential of this approach for B-cell malignancies.
Article Abstract
In this issue of , Green et al identified an innovative and promising pretargeted radioimmunotherapy (RIT) approach for the treatment of non-Hodgkin lymphoma (NHL) and multiple myeloma. Pretargeted RIT of B-cell malignancies with a CD38 bispecific monoclonal antibody (mAb) is a novel approach, and the results achieved in preclinical models are very impressive. CD38 is an excellent target because it has high density and stable expression in multiple myeloma and NHL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805492 | PMC |
| http://dx.doi.org/10.1182/blood-2017-12-819011 | DOI Listing |
Publication Analysis
Top Keywords
pretargeted rit
8
rit b-cell
8
multiple myeloma
8
cd38 pretargeted
4
b-cell tumors
4
tumors issue
4
issue green
4
green identified
4
identified innovative
4
innovative promising
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!